BRPI0920430A2 - composições e métodos para tratar condições mediadas por metaloproteinase matriz 9 (mmp9) - Google Patents

composições e métodos para tratar condições mediadas por metaloproteinase matriz 9 (mmp9)

Info

Publication number
BRPI0920430A2
BRPI0920430A2 BRPI0920430A BRPI0920430A BRPI0920430A2 BR PI0920430 A2 BRPI0920430 A2 BR PI0920430A2 BR PI0920430 A BRPI0920430 A BR PI0920430A BR PI0920430 A BRPI0920430 A BR PI0920430A BR PI0920430 A2 BRPI0920430 A2 BR PI0920430A2
Authority
BR
Brazil
Prior art keywords
mmp9
compositions
methods
matrix metalloproteinase
mediated conditions
Prior art date
Application number
BRPI0920430A
Other languages
English (en)
Inventor
B Wood Anthony
J Archambeau Gregory
l watson Richard
Original Assignee
Revalesio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/258,210 external-priority patent/US20090274730A1/en
Application filed by Revalesio Corp filed Critical Revalesio Corp
Publication of BRPI0920430A2 publication Critical patent/BRPI0920430A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
BRPI0920430A 2008-10-22 2009-10-22 composições e métodos para tratar condições mediadas por metaloproteinase matriz 9 (mmp9) BRPI0920430A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10745308P 2008-10-22 2008-10-22
US10748008P 2008-10-22 2008-10-22
US12/258,210 US20090274730A1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation
PCT/US2009/061744 WO2010048455A1 (en) 2008-10-22 2009-10-22 Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions

Publications (1)

Publication Number Publication Date
BRPI0920430A2 true BRPI0920430A2 (pt) 2019-09-24

Family

ID=42119683

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0920430A BRPI0920430A2 (pt) 2008-10-22 2009-10-22 composições e métodos para tratar condições mediadas por metaloproteinase matriz 9 (mmp9)
BRPI0920201A BRPI0920201A2 (pt) 2008-10-22 2009-10-22 composicoes e metodos para tratar condicoes mediadas por linfopoetina do estroma timico(tslp)

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0920201A BRPI0920201A2 (pt) 2008-10-22 2009-10-22 composicoes e metodos para tratar condicoes mediadas por linfopoetina do estroma timico(tslp)

Country Status (9)

Country Link
EP (2) EP2364154A4 (pt)
JP (4) JP5688371B2 (pt)
CN (2) CN102257130B (pt)
AU (2) AU2009308302B2 (pt)
BR (2) BRPI0920430A2 (pt)
CA (2) CA2741336A1 (pt)
IL (2) IL212277A0 (pt)
MX (2) MX2011004233A (pt)
WO (2) WO2010048425A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
WO2008052145A2 (en) 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
EP2086668B1 (en) 2006-10-25 2016-11-16 Revalesio Corporation Mixing device and method
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
EP2282719B1 (en) * 2008-04-28 2018-05-30 Revalesio Corporation Compositions and methods for treating multiple sclerosis
EP2285347A4 (en) 2008-05-01 2011-09-21 Revalesio Corp COMPOSITIONS AND METHODS OF TREATING DISORDERS OF THE DIGESTION SYSTEM
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
JP6026998B2 (ja) * 2010-05-07 2016-11-16 リバルシオ コーポレイション 生理的パフォーマンスおよび回復時間を強化するための組成物および方法
EA201300228A1 (ru) 2010-08-12 2013-06-28 Ревалезио Корпорейшн Композиции и способы лечения таупатии
BR112013026064A2 (pt) * 2011-04-13 2019-09-24 Revalesio Corp composições e métodos para inibir e/ou modular células t efetoras envolvidas em doença inflamatória neurodegenerativa
CN102250213B (zh) * 2011-07-01 2012-11-07 中国药科大学 基质金属蛋白酶-9多肽抑制剂3及其应用
CN102268070B (zh) * 2011-07-01 2012-11-28 中国药科大学 基质金属蛋白酶-9多肽抑制剂2及其应用
CN102268069B (zh) * 2011-07-01 2012-11-28 中国药科大学 基质金属蛋白酶-9多肽抑制剂4及其应用
KR101492435B1 (ko) * 2012-12-28 2015-02-10 고려대학교 산학협력단 ＨＩＦ­１α ｓｉＲＮＡ를 유효성분으로 함유하는 ＴＳＬＰ에 의해 매개되는 질환 예방 또는 치료용 약제학적 조성물
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN105477628B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 抗癌组合物及其用途
CN106943593A (zh) * 2017-03-24 2017-07-14 浙江中医药大学 抗tslp抗体在制备防治慢性瘙痒药物中的应用
US11345758B2 (en) 2017-06-27 2022-05-31 Translational Sciences, Inc. Inhibition of vascular matrix metalloproteinase-9 to treat ischemic injury
BR112021023035A2 (pt) * 2019-05-17 2022-01-25 Univ Pennsylvania Métodos e composições para tratar obesidade e/ou transtornos cutâneos
CN112876564B (zh) * 2019-11-29 2022-07-15 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140980A0 (en) * 1998-07-28 2002-02-10 Univ California Nucleic acids encoding a g-protein coupled receptor involved in sensory transduction
CN101850120A (zh) * 1999-07-21 2010-10-06 奥默罗斯公司 用于抑制疼痛,炎症和软骨退化的溶液及方法
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
US20030232114A1 (en) * 2002-06-13 2003-12-18 Nikola Dekleva Method for liquid enrichment with oxygen and applications of enriched liquids
WO2004022098A1 (en) * 2002-09-09 2004-03-18 Borsos Ferenc Oxygen-enriched water, treated within a magnetic field and heavy water
US20070077553A1 (en) * 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
WO2004071436A2 (en) * 2003-02-10 2004-08-26 Thomas Jefferson University The use of gcc ligands
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7393924B2 (en) * 2004-01-06 2008-07-01 Franco Vitaliano Smart bio-nanoparticle elements
KR100583430B1 (ko) * 2004-03-08 2006-05-24 양경숙 차륜 가변형 스쿠터
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
WO2008018932A2 (en) * 2006-05-01 2008-02-14 The Board Of Trustees Of The Leland Stanford Junior University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
US20080014247A1 (en) * 2006-06-30 2008-01-17 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
CA2667614A1 (en) * 2006-10-25 2008-09-25 Revalesio Corporation Method of wound care and treatment
EP2086668B1 (en) * 2006-10-25 2016-11-16 Revalesio Corporation Mixing device and method
WO2008052145A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
CA2703672A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
EP2282719B1 (en) * 2008-04-28 2018-05-30 Revalesio Corporation Compositions and methods for treating multiple sclerosis

Also Published As

Publication number Publication date
CN102257130A (zh) 2011-11-23
EP2364154A1 (en) 2011-09-14
CA2741341A1 (en) 2010-04-29
CN102256607B (zh) 2014-11-05
JP5688370B2 (ja) 2015-03-25
WO2010048425A1 (en) 2010-04-29
JP5688371B2 (ja) 2015-03-25
EP2350263A4 (en) 2013-07-03
CN102257130B (zh) 2016-07-06
AU2009308302B2 (en) 2016-01-21
JP2012506453A (ja) 2012-03-15
EP2364154A4 (en) 2013-07-10
IL212309A0 (en) 2011-06-30
WO2010048455A1 (en) 2010-04-29
CA2741336A1 (en) 2010-04-29
JP2015044868A (ja) 2015-03-12
MX337035B (es) 2016-02-09
MX2011004233A (es) 2011-06-24
AU2009308302A1 (en) 2010-04-29
BRPI0920201A2 (pt) 2019-09-10
EP2350263A1 (en) 2011-08-03
IL212277A0 (en) 2011-06-30
CN102256607A (zh) 2011-11-23
IL212309A (en) 2016-04-21
AU2009308362B2 (en) 2016-02-04
AU2009308362A1 (en) 2010-04-29
MX2011004235A (es) 2011-06-24
JP2015044869A (ja) 2015-03-12
JP2012506451A (ja) 2012-03-15

Similar Documents

Publication Publication Date Title
BRPI0920430A2 (pt) composições e métodos para tratar condições mediadas por metaloproteinase matriz 9 (mmp9)
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0819331A2 (pt) Métodos e composições para o tratamento do olho seco
BRPI0909627A2 (pt) métodos, composições e kits para tratar dores e pruridos
BRPI0920326A2 (pt) composição e método para tratamento da síndrome do olho ressecado
BRPI0907183A2 (pt) Método e entidade para encriptação simétrica probabilítica
BRPI0920284A2 (pt) composição e método
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
BRPI0908854A2 (pt) composições e métodos para o tratamento de tumor de origem hematopoética
BRPI0809132A8 (pt) método e aparelhos para pré-peneiramento
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI0913129A2 (pt) método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
BRPI0812509A2 (pt) Aparelho reformador e método
BRPI0921532A2 (pt) dispositivo distribuidor de potencial para distribuição de potencial e processo para distribuição de potencial
BRPI0921959A2 (pt) métodos e composições para remoção de tatuagem
BRPI0719889A2 (pt) Dispositivos e método para multicasting
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI0810525A2 (pt) Composições e métodos para a profilaxia e tratamento de dependência química
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0920920A2 (pt) processo para dessulfuração
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI0913280A2 (pt) dispositivo e método para o tratamento de fluxos de artigos
BRPI0909144A8 (pt) processo para o tratamento de água de descarga e instalação de tratamento de água de descarga
BRPI0907150A8 (pt) dispositivo e método para microelastografia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.